Tumour necrosis factor α (TNF) plays a complex role in the development and progression of tumours.1–4 From early in the development of TNF inhibitors (TNFi), there was concern that their use might lead to an increased risk of malignancy in patients with rheumatoid arthritis (RA). This evidence concerns the gene TNF and neoplasm.